Recent Updates
Recently added Catalysts
TAK Positive Sentiment

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda reported its financial results for the first half of FY2026, highlighting significant achievements. The approval of ORZEYFUL in the U.S., Japan, and China marked a key milestone. Additionally, the U.S. launch of MIMRYLO and progress in the regulatory review of zasocitinib were noted, alongside advancements in the late-stage pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of ORZEYFUL in multiple countries
  • Launch of MIMRYLO in the U.S.
  • Progress in regulatory review of zasocitinib
  • Additional clinical evidence in late-stage pipeline

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Zasocitinib
Phase 3 · Generalized Pustular Psoriasis

Full Press Release Details

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda’s focus remains on execution against the first horizon of its growth strategy: succe

Frequently Asked Questions

What were Takeda's FY2026 first-half results?

Takeda announced significant achievements, including drug approvals and launches.

Which drugs were highlighted in the results?

ORZEYFUL and MIMRYLO were key highlights in Takeda's announcements.

What is ORZEYFUL?

ORZEYFUL (oveporexton) is a drug approved in the U.S., Japan, and China.

What progress was made with zasocitinib?

Takeda reported progress in the regulatory review of zasocitinib.

ShareAdd on Google
Tags: TAK Takeda ORZEYFUL MIMRYLO zasocitinib pipeline milestones
Last updated: Oct 29, 2026

Biotech snapshot

Lead asset
ZasocitinibPhase 3
Generalized Pustular Psoriasis →

Catalyst track record

+36%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →